Reata Pharmaceuticals (NASDAQ:RETA) Upgraded to Outperform at SVB Leerink

SVB Leerink upgraded shares of Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) from a market perform rating to an outperform rating in a research note issued to investors on Monday, PriceTargets.com reports. Several other research analysts have also issued reports on RETA. SVB Securities raised Reata Pharmaceuticals from a market perform rating to an outperform rating […]

Related Keywords

China ,Robertw Baird ,Andrea Loewen ,Michaeld Wortley ,Reata Pharmaceuticals ,News Ratings For Reata Pharmaceuticals Daily ,Barclays ,Reata Pharmaceuticals Stock ,International Assets Investment Management ,Insider Transactions At Reata Pharmaceuticals ,Nisa Investment Advisors ,Reata Pharmaceuticals Inc ,Tower Research Capital ,Belpointe Asset Management ,China Universal Asset Management Co ,Securities Exchange Commission ,Citigroup ,Analyst Recommendations For Reata Pharmaceuticals ,Get Rating ,Moderate Buy ,Exchange Commission ,Asset Management ,Assets Investment Management ,Universal Asset Management ,Investment Advisors ,Research Capital ,Reata Pharmaceuticals Daily ,